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ABSTRACT 
Implantable cardioverter-defibrillator (ICD) therapy remains a corner stone of sudden cardiac 
death (SCD) prevention in patients with arrhythmogenic right ventricular cardiomyopathy 
(ARVC). We aimed to assess predictors of appropriate ICD therapies in the Scandinavian 
cohort of ARVC patients who received ICD for primary prevention of SCD. Study group 
comprised of 79 definite ARVC patients by 2010 Task Force criteria (60% male, age at ICD 
implant 39±14 years) who were enrolled in the Nordic ARVC Registry and received an ICD 
for primary SCD prevention. The primary endpoint of appropriate ICD shock or death from 
any cause was assessed and compared with 137 definite ARVC patients who received ICD for 
secondary SCD prevention (74% male, age at ICD implant 42±15 years). In the study group, 
38% were ≤35 years of age at baseline, 25% had non-sustained VT and 29% had syncope at 
baseline. Major repolarization abnormality (HR=4.00, 95%CI 1.30 – 12.30, p=0.015) and age 
≤35 years (HR=4.21, 95%CI 1.49–11.85, p=0.001) independently predicted the primary 
endpoint. The outcome did not differ between the primary prevention patients with either of 
these risk factors and the secondary prevention cohort (2-4% annual event rate) while patients 
without risk factors did not have any appropriate ICD shocks during follow up. In conclusion, 
young age at ARVC diagnosis and major repolarization abnormality independently predict 
ICD shocks or death in the primary prevention ICD recipients and associated with the event 
rate similar to the one observed in the secondary prevention cohort. Our data indicate the 
benefit of ICD for primary prevention in patients with any of these risk factors. 
 
KEY WORDS: arrhythmogenic right ventricular cardiomyopathy; implantable cardioverter-
defibrillator; sudden cardiac death, prevention  
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INTRODUCTION 
Increased awareness of arrhythmogenic right ventricular cardiomyopathy (ARVC) as a 
progressive inherited disease associated with the risk of sudden cardiac death (SCD) has lead to 
implementation of family screening strategies in clinical management guidelines
1
 and revision 
of diagnostic criteria, which increased their sensitivity.
2
 As a result, the number of ARVC 
patients requiring risk stratification regarding implantation of an implantable cardioverter-
defibrillator (ICD) for primary prevention of SCD is growing. While secondary prevention ICD 
implantation in ARVC is based on a well-documented increased risk of life-threatening 
ventricular arrhythmias,
3-5
 the literature regarding the primary prevention ICD indications is 
limited.
6, 7
 We aimed to assess the predictors of ICD therapy in a large unselected cohort of 
patients with definite ARVC, who were diagnosed according to 2010 Task Force criteria 
(TFC2010) and received ICD implants for primary prevention of SCD, and compare the 
prognosis with secondary prevention ICD recipients, who represent an a priori high risk group 
in regard to ventricular arrhythmia recurrence. We also aimed to evaluate the risk factors 
associated with appropriate ICD therapies, identify patients at the highest risk of ventricular 
arrhythmias and describe subgroups of low risk patients, in whom ICD implantation for 
primary prevention may not be needed.  
METHODS 
The Nordic ARVC Registry (www.arvc.dk) was launched in June 2010 and includes 
patients diagnosed with definite ARVC by TFC2010 and followed through ICD outpatient 
clinics  and dedicated cardio-genetics units affiliated with tertiary referral centers in 
Scandinavia.
8
 We also prospectively recruit newly diagnosed patients. The register captured 
baseline clinical characteristics and the data specific for ARVC diagnostic criteria as proposed 
in the original Task Force recommendations from 1994
9
 and the updated TFC2010.
2
 
Ventricular tachyarrhythmia data included in the registry are reported either as ECG-verified 
ventricular tachycardia or as captured by ICD device diagnostics. Historical information 
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regarding ventricular tachycardia (VT) prior to ARVC diagnosis or ICD implantation was 
retrieved from patients’ medical records as assessed by a cardiology specialist. 
Decision to implant ICD for primary prevention of SCD was guided by guideline 
documents, which were in force at the time when patients underwent clinical evaluation
10, 11
 
and local practice. Patients who received ICD after aborted cardiac arrest or documented 
sustained VT were considered secondary prevention ICD recipients while all other, including 
those with documented non-sustained VT, were considered as a primary prevention cohort. 
Secondary prevention ICD patients were used for comparison of clinical characteristics and 
clinical outcomes observed in the primary prevention group. Prospective follow-up information 
was available until November 2017. Regional ethics committees approved the study. In 
Denmark, the approval was obtained from the Danish Data Protection Agency. The study 
complies with the Declaration of Helsinki. 
Continuous data are presented as mean ± standard deviation. Nominal data are presented as 
number (% of cases). Chi-squared or Fischer’s exact test was used for comparison between 
categorical variables, and t-test was used for the comparison of continuous variables.  
The primary study endpoint was appropriate ICD shock or death from any cause. The 
secondary study endpoint was any appropriate ICD therapy defined as either antitachycardia 
pacing (ATP) or shock or death from any cause. Subjects who did not have any appropriate 
ICD therapy were censored at the end of follow-up or heart transplantation. Kaplan–Meier 
product-limit method was used to generate a survival curve indicating time to endpoint from 
the ICD implantation date. Cox proportional hazard regression models were used to estimate 
the adjusted hazard ratios (HR) and their 95% confidence intervals (CI). Cox regression 
analyses were performed on the primary prevention cohort while the Kaplan Meier curves 
representing the outcome in the secondary prevention cohort were included for comparison of 
cumulative incidence of ICD therapies with the a priori high risk ARVC patients. 
Univariable Cox regression analyses were performed for each component of TFC2010, 
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including imaging and ECG characteristics, gender, age, and history of syncope or VT prior to 
ICD implantation. The impact of age was assessed as a continuous variable and dichotomized 
using 35 years as a threshold as earlier proposed.
6
 Since the proband status, which in previous 
studies was reported a predictor of arrhythmic events in ARVC,
7
 indicates the first individual in 
a family from whom cascade screening is initiated, the proband status per se may not 
necessarily be related to the presence of phenotypical characteristics of the disease. Therefore it 
was substituted by the `Definite ARVC by phenotype´ status defined as individuals who fulfill 
TFC2010 for definite ARVC diagnosis without accounting for the family history or mutation 
carrying status. Multivariable analysis was performed only individual phenotypical 
characteristics of the disease, which demonstrated p-value <0.15 in the univariable analysis 
thus excluding composite disease characteristics such as proband status and the Definite ARVC 
by phenotype status. Multivariable analysis included a stepwise backward elimination using 
logistic regression. A two-sided P-value of 0.05 was considered statistically significant. 
RESULTS 
Of the total number of 296 patients with definite ARVC recruited by November 2017, 216 
had an ICD implanted. ICD was implanted for secondary prevention of SCD in 137 patients 
while 79 patients constituted the primary prevention cohort (Table 1). One third of the study 
population was recruited prospectively with newly diagnosed ARVC after June 2010: 45 (33%) 
in the secondary and 23 (29%) in the primary prevention group.  
Left ventricular (LV) involvement defined as reduced LV ejection fraction ≤40% was 
uncommon. A large proportion of patients underwent cardiac magnetic resonance imaging 
(CMR) in addition to a conventional echocardiography, which was performed in all subjects. 
Few patients underwent myocardial biopsy, which was performed on the RV free wall in only 9 
subjects (4.2%) and on the RV septum in 59 (27%).  
Genetic evaluation was performed in more than 80% of probands from both the secondary 
and primary prevention groups and in nearly half of the tested individuals it yielded positive 
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identification of a disease-causing genetic variant (n=93, 52%). The vast majority of mutation-
positive probands carried a mutation in the plakophillin-2 (PKP2) gene (63%), followed by 
desmoglein-2 (DSG2, 18%), desmoplakin (DSP, 14%), DSC-2 (5.3%), TMEM43 (3.2%). Four 
patients had mutations identified in 2 desmosomal genes.  
Primary asymptomatic patients, i.e. those who were diagnosed through cascade family 
screening and did not have any symptoms or documented ventricular arrhythmias prior to 
diagnosis constituted one third of the primary prevention cohort (n=25, 30%).   
During a median follow-up of 89 [IQR 58 - 146] months after ICD implantation, 22 
patients underwent heart transplantation and five died. One death occurred in the primary 
prevention group (cause unknown) and 4 in the secondary prevention group (2 non-cardiac, 1 
within a month after heart transplantation and 1 unknown).  
By the end of follow-up, 81 patients had experienced appropriate shocks (18 [23%] in the 
primary prevention and 63 [46%] in the secondary prevention group, p=0.002), while 147 
experienced either appropriate shocks or ATP (46 [58%] in the primary prevention and 107 
[78%] in the secondary prevention group, p=0.004). Out of 24 primary asymptomatic patients, 
13 had ATP during follow-up and none experienced ICD shock. Inappropriate ICD shocks 
were seen in 24 patients and occurred with similar 10-year cumulative incidence among 
patients from primary vs secondary prevention cohort (15% vs 11%, p=0.839). 
Results of univariable Cox regression analyses performed for the disease manifestations 
and diagnostic work up data are presented in Supplemental Table 1. The proband status, 
definite ARVC by phenotype status, young age (35 years), the major repolarization and the 
major depolarization criteria were significantly associated with primary endpoint in the 
univariable analysis. RV ejection fraction demonstrated a borderline significant inverse 
association with the primary outcome in the univariate analysis but was available only for the 
subset of patients who underwent CMR and therefore not included in the multivariate analysis. 
Proband status and definite ARVC by phenotype status, being composite characteristics of the 
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disease phenotype, were not included in the multivariable model together with individual 
phenotypical features of the disease.  
Young age (35 years), major repolarization criterion, major depolarization criterion and 
the history of syncope entered the multivariable model that was also adjusted for gender. After 
stepwise backward elimination process using logistic regression, the age 35 and the presence 
of major repolarization criterion were included in the final model and appeared to be 
independent predictors of appropriate ICD shocks. For the secondary endpoint, only the major 
repolarization criterion remained the independent predictor of the outcome in the multivariable 
analysis (Table 2). 
Figure 1 presents the outcome among the primary prevention cohort grouped by the 
presence of the risk factors identified in the multivariate analysis (age  35 years, major 
repolarization criterion). The presence of 2 risk factors was associated with the cumulative risk 
of events similar to the one demonstrated by the secondary prevention cohort while primary 
prevention patients who did not have either of the risk factors did not experience any 
appropriate ICD shock. C-statistics for the risk factor model was 0.80 (95%CI 0.69-0.89) for 
the primary and 0.62 (95%CI 0.50-0.75) for the secondary endpoints. 
Cumulative risk of the study endpoints in the primary prevention group categorized by the 
presence of distinct disease phenotype, i.e. fulfillment of the definite ARVC diagnosis based on 
the phenotypical characteristics of the disease only and not requiring criteria from the family 
history or genetics, is presented in Figure 2. Primary prevention ICD carriers had cumulative 
incidence of appropriate ICD therapies in the same range as the secondary prevention cohort. 
On the other hand, the incidence of appropriate ICD shocks in patients without either of the risk 
factors or not fulfilling definite ARVC diagnosis without family history/genetic information 
was low and corresponded to the annual rate of 0-0.7% (Supplemental Table 2). 
DISCUSSION 
Our findings are based on the Scandinavian cohort of patients with definite ARVC who 
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received ICD implants for primary or secondary prevention of SCD. Two risk factors, young 
age and major repolarization criterion by ECG, each independently predicted appropriate ICD 
shocks or death among patients who received ICD for primary prevention of SCD. The 
cumulative incidence of appropriate ICD therapies in the primary prevention patients who had 
either of these two risk factors was similar to the one observed in the secondary prevention 
cohort. Patients with ARVC phenotype becoming apparent after 35 years of age who do not 
manifest with major repolarization abnormality or require family history/genetic criterion in 
order to fulfill definite ARVC diagnosis constitute a low risk group in regard to arrhythmic 
complications of the disease and may not require primary prevention ICD implantation. 
Clinical characteristics of primary prevention ICD recipients demonstrate significant 
variability in the literature, which may affect the results of analyses yielding different clinical 
characteristics as independent predictors of arrhythmic outcomes. Our patients can be 
compared with two earlier reported primary prevention cohorts
6, 7
 and the most recent report 
from the North American multidisciplinary study of ARVC, which included 56 patients who 
received ICD for primary prevention indication
12
 (Table 3).  
Similarly to the Johns Hopkins cohort,
7
 our patients were diagnosed by TFC2010 and 
therefore also included patients with less severe disease manifestations. The prevalence of a 
history of syncope in our group was also remarkably similar to others.
7, 12
 While being similar 
in regard to the ECG phenotype, our patients were older at ICD implantation, more often were 
men, and had less family members enrolled in the study than reported by Bhonsale et al.
7
 The 
proportion of family members, who commonly demonstrate mild disease phenotype and low 
risk of arrhythmic complications of the disease, which may affect risk estimations, was 
strikingly similar in our and Johns Hopkins cohort.
7
 The rate of ICD interventions, such as 
cumulative incidence of any appropriate ICD therapy by 10 years of follow-up is also similar to 
earlier reported being  63% in the Johns Hopkins cohort compared to 67% in ours. 
While syncope is a recognized risk factor in patients with ARVC and is listed as a class 
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IIb indication
11
 for ICD implantation, the data supporting this recommendation came mostly 
from the study on patients diagnosed by TFC1994
6
 while contemporary primary prevention 
studies
7,12
  did not support syncope as an independent predictor of appropriate ICD therapy. 
Our findings of the syncope lacking any predictive value for appropriate ICD therapies are 
therefore in accord with earlier findings in the primary prevention settings. 
Previously published data in support of NSVT as a risk marker give a mixed picture. 
Although most of studies report NSVT as a predictor of appropriate ICD therapies un 
univariate analyses,
4, 6, 13
 this was not supported by all
14
 and only one earlier study devoted to 
the primary prevention found it to be an independent predictor of appropriate ICD therapies.
7
 In 
our cohort, the prevalence of NSVT prior to ICD implantation is much lower than the one 
reported in the Johns Hopkins cohort.
7
 Additional studies are therefore needed to resolve the 
uncertainty regarding predictive value of NSVT as a SCD risk indicator. 
It has been observed that arrhythmic manifestations of ARVC are linked to other 
phenotypic characteristics of the disease
15
 and its progression to the overt phenotype, which 
can be assessed as the age of ARVC diagnosis. Earlier data have consistently reported that 
younger age at diagnosis was associated with VT during follow-up.
6, 7, 12, 13
 Our findings are in 
line with these previous observations and support the use of age at disease presentation as a risk 
marker of arrhythmic events during follow-up.  Though the age at ICD implantation was 
included in the multivariable analysis as the time point for the start of follow-up in order to 
capture the study endpoints defined as appropriate ICD therapies or death, the mean difference 
between the age at diagnosis and the age at ICD implantation was less than one year and was 
not different between the groups.  
Our data suggest that early disease manifestation or T-wave inversion meeting criteria for 
major repolarization criteria are associated with 4-fold increased risk of appropriate ICD 
shocks or death. Cumulative incidence of ICD therapies in high-risk patients from the primary 
prevention cohort was also found to be very similar to the incidence observed among the 
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secondary prevention cohort. This further illustrates the primary prevention risk stratification 
challenge as, based on our findings, patients with early disease manifestations may be expected 
to received ICD therapies to the same extent as secondary prevention ARVC patients. 
Among the diagnostic criteria, which constitute the disease phenotype, ECG 
characteristics that reflect depolarization and repolarization abnormalities meeting definitions 
for major criteria appeared to be univariate predictors of the primary endpoint, of which 
abnormal ventricular repolarization consistent with the major diagnostic criterion appeared to 
be the strongest predictor while arrhythmic criteria were not significantly associated with the 
outcome.  
While the use of ICD therapies and inclusion of ATP in the secondary endpoint may 
overestimate the life-saving efficacy of ICD therapy, the lack of ICD therapies can be used for 
identification of patients who would not benefit from ICD implantation. Our data further 
support earlier observations that family members, and primary asymptomatic family members 
in particular, are at low risk of arrhythmic events.
7, 16
 In our study, primary asymptomatic 
patients did not have any appropriate ICD shocks during follow-up. 
Our cohort consists of patients who were under clinical follow-up by the register launch 
in June 2010 and those who were prospectively enrolled with newly diagnosed ARVC since 
then, which is a limitation of the study. However, the main endpoint of the study, i.e. delivery 
of ICD therapies, is governed by strict documentation requirements in the participating 
countries, which supports the validity of the study endpoint. We have not been able to 
distinguish delivery of ICD therapies dependent on the cycle length of VT/VF in our study and 
thus could not reliably distinguish whether ICD shocks were delivered for fast or slow VT. The 
rate of therapy delivery, however, appears to be in the same range as the one reported in an 
earlier contemporary long-term follow-up primary prevention ARVC population,
7
 which 
supports clinical validity of our study findings. Finally, despite being a relatively large study in 
the context of ARVC, the size of our cohort is still not sufficient for definitive conclusions 
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concerning other risk factors, which have not demonstrated predictive value in our study.  
In conclusion, our data based on a contemporary cohort of patients with definite ARVC 
diagnosed using TFC2010 treated with ICD for primary prevention of SCD further supports the 
use of severe disease phenotype, young age at ARVC diagnosis, and electrocardiographic 
ventricular repolarization abnormalities in particular, as the major risk factors predicting 
appropriate ICD therapies. Family history of SCD at young age in a first degree relative was 
not associated with increased risk of ventricular arrhythmic events in primary prevention ICD 
recipients. 
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FIGURE LEGENDS 
 
 
 
Figure 1. Kaplan Meier curve analysis of the risk of the primary (A) or secondary (B) 
endpoints in patients with ascertained ARVC diagnosis. Primary prevention cohort is presented 
as 4 groups (1A-1D) based on the presence of the disease characteristics identified in a 
multivariate analysis as independent predictors of appropriate ICD shocks or death from any 
cause: age at ARVC diagnosis 35 years and major repolarization criterion. Kaplan-Meier 
curves representing the risk of ICD therapies in the secondary prevention cohort is presented 
for comparison. 
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Figure 2. Kaplan Meier curve analyses of the risk of the primary (A) and secondary (B) 
endpoints in patients with ascertained ARVC diagnosis. Primary prevention cohort is presented 
as 4 groups (1A-1D) based on the age of diagnosis and the presence of definite ARVC 
diagnosis by TF2010, not requiring diagnostic criteria from the family history/genetic category. 
Kaplan-Meier curves representing the risk of ICD therapies in the secondary prevention cohort 
is presented for comparison. 
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Table 1. Clinical characteristics of patients with definite ARVC (TF2010) who received ICD 
for primary and secondary prevention of SCD in the Nordic ARVC Registry 
 
Secondary 
prevention 
 
n=137 
Primary 
prevention 
 
n=79 
P-value 
 
 1 2  
Men 101(74%) 47 (60%) 0.022 
Probands 128 (93) 51 (65) <0.001 
Definite ARVC by TFC2010 criteria without Family 
history/Genetics  
122 (89)    53 (67) <0.001 
Age at ICD implantation (years) 4215 3914 0.154 
Age at diagnosis (years) 4116 3814 0.093 
Age ≤35 years at ICD implantation, n (%) 47 (34) 30 (38) 0.345 
SCD in a 1st degree relative <35 years 8 (6) 11(15) 0.038 
Competitive athlete 57 (42%) 15 (19%) <0.001 
VT prior to ICD implantation
a
 111 (81%) 20 (25%) <0.001 
Syncope prior to ICD implantation 25 (18%) 23 (29%) 0.048 
Imaging criterion, major 108 (79%) 53 (67%) 0.041 
Imaging criterion, minor 113 (83%) 57 (72%) 0.054 
LVEF (%) 568 5312 0.308 
LVEF ≤40% 9 (6.6%) 8 (10%) 0.248 
Cardiac CMR performed 97 (71%) 40 (50%)  
   RVEF by CMR (%) 399 4114 0.367 
   RVEDV/BSA by CMR (ml/m
2
) 12932 11852 0.009 
   LGE-positive 33 (44%) 10 (25%) 0.321 
Tissue criterion major 5 (3.6%) 3 (4%) 0.612 
Tissue criterion minor 0 0 N/A 
Repolarization criterion major 73(53%) 39 (49%) 0.339 
Repolarization criterion minor 87 (64%) 47 (61%) 0.398 
Depolarization criterion major 13 (9.5%) 6 (7.6%) 0.419 
Depolarization criterion minor 92 (67%) 36 (46%) 0.002 
T-wave inversion inferior 41 (30%) 18 (23%) 0.165 
Arrhythmia criterion major  61 (45%) 13 (17%) <0.001 
Arrhythmia criterion minor  123 (89%) 71 (90%) 0.590 
Family history criterion major 78 (57%) 58 (73%) 0.011 
Family history criterion minor 1 (0.7%) 8 (10%) 0.002 
Genetic evaluation performed in probands 104 (81%) 42 (82%) 1.000 
Desmosomal mutations in probands 68 (53%) 25 (49%) 0.024 
a)
 – For the primary prevention group, VT history concerns history of non-sustained VT. 
ARVC – arrhythmogenic right ventricular cardiomyopathy; BSA – body surface area; CMR – cardiac 
magnetic resonance imaging; ICD – implantable cardioverter-defibrillator; LGE – late gadolinium 
enhancement; LVEF – left ventricular ejection fraction; RVEDV – right ventricular end-diastolic 
volume; RVEF – right ventricular ejection fraction; TFC – Task Force criteria; SCD – sudden cardiac 
death; VT – ventricular tachycardia 
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Table 2: Results of the multivariable analysis of appropriate ICD therapy predictors in the 
primary prevention ARVC cohort. Age <35 years, major repolarization abnormality, major 
depolarization abnormality and the history of syncope were included in the multivariable model 
that was adjusted for gender.  
 
  
Multivariable Cox regression 
HR 95% Confidence interval p-value 
Any appropriate ICD shock or death from any cause 
Age < 35 years 4.21 1.49 11.85 0.006 
Major repolarization abnormality 4.00 1.30 12.30 0.015 
Any appropriate ICD shock or ATP or death from any cause 
Major repolarization abnormality 2.32 1.22 4.43 0.010 
ARVC – arrhythmogenic right ventricular cardiomyopathy; ATP – antitachycardia pacing; HR 
– hazard ratio; ICD – implantable cardioverter-defibrillator;  
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Table 3. Clinical characteristics of ARVC patients with definite diagnostic category by 
TFC2010 from contemporary primary prevention cohorts. 
 
Bhonsale 
2011
7
 
Link 
2014
12
 
Nordic ARVC 
Registry 
Variable n=84* n=56 n=79 
Age (years) 32±12 40±14 39±14 
Male gender 46% 60% 60% 
Mean follow-up duration (months) 57 29 89 
History of syncope 27% 25% 29% 
History of  NSVT 49% 16% 25% 
Family History of SCD 17% 17%‡ 15% 
Right precordial T-wave inversion (V1-V3) 68% 76% 49% 
Major RV abnormality 29% 71%‡ 67% 
LVEF <55% 25% 13%‡ 24% 
* - Only 70 of 84 patients fulfilled criteria for definite ARVC. 
‡
 - data not published, provided 
by North American multidisciplinary ARVC study team. ARVC – arrhythmogenic right 
ventricular cardiomyopathy; LVEF – left ventricular ejection fraction; NSVT – non-sustained 
ventricular tachycardia; SCD – sudden cardiac death. 
 
